Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.

JAMA Neurol · 2022 · PMC9468959 · PMID 36094645

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The disease-progression model uses all of the available time-course data and shows a highly significant predicted association between percentage amyloid plaque reduction from baseline and slowing of cognitive decline for APOE ε4 carriers.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.